Drugs / Molidustat
last change Dec 2019 re-read 2 minutes ago

Molidustat

Small molecule targets EGLN1, EGLN2, EGLN3 via inhibition

Developed for
anemia · chronic kidney disease
Investigated by
Bayer

Trials 15 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT02312973 Jan → Dec 2015 chronic kidney disease Bayer Completed No outcome recorded
Phase 1 NCT01679587 Sep 2012 → Feb 2013 kidney disorder Bayer Completed No outcome recorded
Phase 1 NCT01458028 Sep → Dec 2011 anemia Bayer Completed No outcome recorded
Phase 1 NCT01332942 Apr 2011 → May 2013 anemia Bayer Completed No outcome recorded
Phase 1 NCT01318551 Mar 2011 → Sep 2013 anemia Bayer Completed No outcome recorded
Phase 25 trials
Phase 2 NCT02055482 Jun 2014 → Nov 2016 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 2 NCT02064426 Mar 2014 → Oct 2016 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 2 NCT02021370 Feb 2014 → Sep 2015 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 2 NCT02021409 Jan 2014 → Oct 2015 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 2 NCT01975818 Oct 2013 → Oct 2015 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 35 trials
Phase 3 NCT03543657 Jun 2018 → Aug 2019 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 3 NCT03418168 Feb 2018 → Jul 2019 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 3 NCT03351166 Jan → Oct 2018 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 3 NCT03350347 Dec 2017 → Jul 2019 anemia, chronic kidney disease Bayer Completed No outcome recorded
Phase 3 NCT03350321 Dec 2017 → May 2019 anemia, chronic kidney disease Bayer Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

FieldValueCited text
Known as Molidustat “Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).” NCT01332942
10

NCT03350321

NCT02055482

NCT01679587

NCT02312973

NCT03418168

NCT03350347

NCT01975818

NCT03543657

NCT03351166

NCT02064426

Known as BAY 1053048 ChEMBL registry synonym — accepted as the source's own label CHEMBL3646118
Known as BAY-85-3934 SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL3646118
Known as BAY85-3934 “Investigation of Pharmacokinetics, Safety, Tolerability, and Pharmacodynamic Effects of BAY85-3934 in Male and Female Subjects With Renal Impairment and in Age- and...” NCT01318551
15

“Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets” NCT02021409

“Molidustat (BAY 85-3934)” NCT01975818

“Molidustat (BAY85-3934)” NCT03418168

“Molidustat (BAY85-3934)” NCT03351166

“Molidustat (BAY85-3934)” NCT02055482

“Molidustat (BAY85-3934)” NCT03350347

“Molidustat (BAY85-3934)” NCT01679587

“Molidustat (BAY85-3934)” NCT02064426

“Molidustat (BAY85-3934)” NCT03350321

“Molidustat (BAY85-3934)” NCT03543657

“Molidustat(BAY85-3934)” NCT02312973

NCT02021370

NCT01458028

NCT01318551

NCT02021409

Known as MOLIDUSTAT SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL3646118
Action Inhibit “Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor” CHEMBL3646118
3

“Molidustat is an oral HIF-PH inhibitor” PMID 31203242 Jun 2019

“Egl nine homolog 1 inhibitor” CHEMBL3646118

“Egl nine homolog 3 inhibitor” CHEMBL3646118

Modality Small molecule CHEMBL3646118
Route Oral “single oral dose” NCT01318551
Target EGLN1 “Egl nine homolog 1 inhibitor” CHEMBL3646118
Target EGLN2 “Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor” CHEMBL3646118
Target EGLN3 “Egl nine homolog 3 inhibitor” CHEMBL3646118